Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:1548
SEHK:1548Life Sciences

A Look At Genscript Biotech (SEHK:1548) Valuation After CARVYKTI Q4 2025 Sales Momentum

Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction. See our latest analysis for Genscript Biotech. Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...
NasdaqGM:ALT
NasdaqGM:ALTBiotechs

Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...